Welcome to the e-CCO Library Archive!
Phlegmonous Crohn's disease: A review of outcomes at a tertiary centre
K.V. Patel*1, C.I. Amadi1, S. Fong1, I. Nasr1, N. Griffin2, E. Westcott3, A.B. Williams3, A.A. Darakhshan3, S.H. Anderson1, P.M. Irving1, J.D. Sanderson1
1Guy's and St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom, 2Guy's and St Thomas' NHS Foundation Trust, Radiology, London, United Kingdom, 3Guy's and St Thomas' NHS Foundation Trust, Colorectal Surgery, London, United Kingdom
Biological agents in Crohn's disease: When?
E. Saritas Yuksel1, C. Cekic1, F. Topal1, Z.Z. Gumus1, B. Unsal1, Z. Akpinar1, 1IKÇU Ataturk Research and Teaching Hospital, Gastroenterology, Izmir, Turkey
R. Vadan1, L. Gheorghe1, R. Cerban1, B. Cotruta1, L. Tugui1, I. Stanel1, C. Angelescu1, I. Bancila1, M. Diculescu1, C. Gheorghe1, 1Fundeni Clinical Institute, Gastroenterology and Hepatology Center, Bucharest, Romania
Early intervention of infliximab prevent reoperation for the recurrence of Crohn's disease
M. Ishii*1, K.-i. Tarumi1, T. Kamada1, M. Fujita1, H. Matsumoto1, T. Murao1, R. Nakato1, M. Osawa1, S. Hirai1, S. Fukushima1, N. Manabe2, H. Kusunoki3, A. Shiotani1, J. Hata2, K. Haruma1
1Kawasaki Medical School, Division of Gastroenterology Department of Internal Medicine, Kurashiki, Japan, 2Kawasaki Medical School, Clinical Pathology and Laboratory Medicine, Kurashiki, Japan, 3Kawasaki Medical School, Genaral Medicine, Kurashiki, Japan
Azathioprine in the elderly – Is it tolerated and is it safe?
S. Dharmasiri, H. Johnson, S. McLaughlin, S. Weaver, Royal Bournemouth Hospital, Depatment of Gastroenterology, Bournemouth, United Kingdom
M. Cesarini1, K. Katsanos2, P. Ellul3, P. Lakatos4, K. Papamichael5, F. Caprioli6, E. Tsianos2, G. Mantzaris5, S. Danese7, G. Fiorino7, 1Sapienza University of Rome, Medicina Interna e Specialità Mediche, Rome, Italy, 2University of Ioannina, Greece, 3Mater Dei Hospital, Malta, 4Semmelweis University, Budapest, Hungary, 5Evangelismos Hospital, Athens, Greece, 6University of Milan, Italy, 7IRCCS Humanitas, IBD Center, Rozzano, Italy
Short and long term therapeutic Efficacy of Oral Nutritional Therapy in pediatric Crohn's Disease ; A Single Center Experience
H.J. Kim*, J.M. Cho, K.M. Kim, S.H. Oh
Seoul Asan Medical Center , Pediatrics , Seoul , South Korea
Azathioprine and lymphocyte count in paediatric inflammatory bowel disease
E. Volonaki, V. La Vela, R. Dziubac, F. Kiparissi, N. Shah, K.J. Lindley, M. Elawad, Great Ormond Street Hospital, Paediatric Gastroenterology, London, United Kingdom
E. De Greef1, B. Maus2, I. Hoffman3, F. Smets4, S. Van Biervliet5, M. Scaillon6, B. Hauser7, I. Paquot8, P. Alliet9, W. Arts10, O. Dewit11, H. Peeters12, F. Baert13, G. D'Haens14, J.-F. Rahier15, I. Etienne16, O. Bauraind8, A. Van Gossum17, S. Vermeire18, F. Fontaine19, V. Muls20, E. Louis21, F. Van De Mierop22, J. Coche23, J.J. Mahachie2, K. Van Steen2, G. Veereman24, 1UZ Brussels, Pediatric Gastroenterology, Jette, Belgium, 2ULG, Montefiore Institute, Liege, Belgium, 3Uz Gasthuisberg, Pediatric Gastroenterology, Leuven, Belgium, 4UCL St Luc, Pediatric Gastroenterology, Brussel, Belgium, 5UZ Gent, Pediatric Gastroenterology, Gent, Belgium, 6Hôpital des enfants Reine Paola, Pediatric Gastroenterology, Brussel, Belgium, 7UZ Brussels, Pediatric Gastroenterology, Brussel, Belgium, 8CHC Clinique de l'Esperance, Pediatric Gastroenterology, Liege, Belgium, 9Jessa Hospital, Pediatric Gastroenterology, Hasselt, Belgium, 10ZOL, Pediatric Gastroenterology, Genk, Belgium, 11UCL St Luc, Gastroenterology, Brussel, Belgium, 12UZ Gent, Gastroenterology, Gent, Belgium, 13Heilig Hart Hospital, Gastroenterology, Roesselare, Belgium, 14AMC, Gastroenterology, Amsterdam, Netherlands, 15UCL Montgodinne, Gastroenterology, Mont Godinne, Belgium, 16CHR Citadelle, Pediatric Gastroenterology, Liege, Belgium, 17ULB Erasme, Gastroenterology, Brussel, Belgium, 18Uz Gasthuisberg, Gastroenterology, Leuven, Belgium, 19CHU St Joseph, Gastroenterology, Liege, Belgium, 20ULB St Pierre, Gastroenterology, Brussel, Belgium, 21ULG, Gastroenterology, Liege, Belgium, 22AZ St Augustinus, Gastroenterology, Wilrijk, Belgium, 23Clinique Saint Pierre, Gastroenterology, Ottignies, Belgium, 24UZ Brussels, Pediatric Gastroenterology, Brussels, Belgium
Long - term efficacy of Tacrolimus in Inflammatory Bowel Disease: a retrospective pilot study
I. Rodríguez - Lago*1, O. Merino2, Ó. Nantes3, I. Moraleja1, J.L. Cabriada1
1Hospital Galdakao - Usansolo, Gastroenterology Department, Usansolo, Spain, 2Hospital Universitario de Cruces, Gastroenterology Department, Bilbao, Spain, 3Complejo Hospitalario de Navarra, Gastroenterology Department, Pamplona, Spain
Association between haemoglobin levels, serum ferritin and faecal and serum markers of inflammation in patients with IBD
N.S. Taylor, S. Cotton, L.-A. McCabe, D.A. Lloyd, J.N. Gordon, Royal Hampshire County Hospital, Hampshire Hospitals NHS Foundation Trust, Department of Gastroenterology, Winchester, United Kingdom
A. Eser1, C. Primas1, S. Haunstein2, S. Lockton2, S. Wang2, S. Singh2, W. Reinisch1, 1Medical University of Vienna, Vienna, Austria, 2Prometheus Labs Inc, San Diego, United States
Hospital readmissions in patients with inflammatory bowel disease: A UK single centre experience
L. Chan*, E. Wood, L. Fang, J. Limdi
Pennine Acute Hospitals NHS Trust, Gastroenterology, Greater Manchester, United Kingdom
Association between Week 8 Mayo subscores and hospitalisation rates in adalimumab-treated patients with ulcerative colitis from ULTRA 1 and ULTRA 2
W. Reinisch1, W.J. Sandborn2, B. Feagan3, S. Ghosh4, A. Robinson5, M. Skup5, J. Petersson5, B. Huang5, A. Lazar6, R. Thakkar5, 1McMaster University, Department of Medicine, Hamilton, Canada, 2University of California San Diego, Division of Gastroenterology, La Jolla, United States, 3Robarts Clinical Trials Inc., Robarts Research Institute, Western University, London, Ontario, Canada, 4University of Calgary, Department of Medicine, Calgary, Canada, 5AbbVie Inc, GPRD, North Chicago, United States, 6AbbVie Deutschland GmbH & Co, KG, GPRD, Ludwigshafen, Germany
I. Blumenstein1, S. Vollmer2, W. Klemm3, G. Virgin4, S. Weber-Mangal4, J. Stein5, 1Frankfurt University Hospital, Medical Dpt. 1, Frankfurt, Germany, 2Gastroenterological Practice, Göppingen, Germany, 3Gastroenterological Practice, Cottbus, Germany, 4Vifor Pharma Germany, Munich, Germany, 5Crohn Colitis Zentrum Rhein-Main, Frankfurt, Germany
Prognosis of patients with Ulcerative Colitis in remission after thiopurines withdrawal
E. Moreno Rincón*1, F.J. Serrano Ruiz1, J.M. Benítez Cantero1, J.M. Vázquez Morón2, H. Pallarés Manrique2, J.M. Herrera Justiniano3, E. Leo Carnerero3, M.D.R. Gómez García4, M.J. Cabello Tapia4, M. Castro Fernández5, M. Rojas Feria5, L. Castro Laria6, F. Argüelles Arias6, R. Camargo Camero7, G. Alcaín Martínez7, E. Iglesias Flores1, V. García Sánchez1
1Hospital Universitario Reina Sofía, Gastroenterology Unit, Córdoba, Spain, 2Hospital Juan Ramón Jiménez, Gastroenterology, Huelva, Spain, 3Hospital Universitario Virgen del Rocío, Gastroenterology, Sevilla, Spain, 4Hospital Universitario Virgen de las Nieves, Digestive Department, Granada, Spain, 5Hospital de Valme, Gastroenterology, Sevilla, Spain, 6Hospital Universitario Virgen Macarena, Gastroenterology, Sevilla, Spain, 7Hospital Universitario Virgen de la Victoria, Gastroenterology, Malaga, Spain
A single-centre pilot study examining internet use for health related information among patients with inflammatory bowel disease
K. Greveson1, T. Shepherd2, M. Hamilton1, C. Murray1, 1Royal Free Hospital, Gastroenterology, London, United Kingdom, 2Royal Free Hospital, Gastroenterology, London, United Kingdom
M. Tanaka1, A. Kawakami1, Y. Iwao2, T. Fukushima3, M. Nishigaki1, M. Suzuki1, H. Sanada1, N. Yamamoto-Mitani1, 1The University of Tokyo, School of Health Sciences and Nursing, Tokyo, Japan, 2Keio University School of Medicine, Center for Preventive Medicine, Tokyo, Japan, 3Matsushima Clinic, Yokohama, Japan
An Evaluation Study of Lactobacillus Brevis CD2 in Orofacial Granuolomatosis
R. Goel*1, 2, M. Ormond1, E. Hullah1, S. Nayee1, M. Escudier1, J. Sanderson3
1Guy's & St Thomas' Hospitals, Oral Medicine, London, United Kingdom, 2Guy's & St Thomas' Hospitals, Gastroenterology, London, United Kingdom, 3Guy's & St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom
A prospective assessment of antidrug antibody response over time by a new ELISA in patients with IBD treated with infliximab
V. Ussia, L. Ceccarelli, S. Maltinti, G. Di Fluri, M.G. Mumolo, V. Bolognesi, A. Ricchiuti, M. Bellini, S. Marchi, F. Costa, Pisa University, Gastroenterology, Pisa, Italy